Compare · BSX vs CVRX
BSX vs CVRX
Side-by-side comparison of Boston Scientific Corporation (BSX) and CVRx Inc. (CVRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and CVRX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $89.10B, about 440.6x CVRX ($202.2M).
- Over the past year, BSX is down 41.3% and CVRX is up 1.9% - CVRX leads by 43.2 points.
- CVRX has been more active in the news (6 items in the past 4 weeks vs 3 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 13 for CVRX).
- Company
- Boston Scientific Corporation
- CVRx Inc.
- Price
- $59.95-3.39%
- $7.65-0.78%
- Market cap
- $89.10B
- $202.2M
- 1M return
- -14.57%
- -17.83%
- 1Y return
- -41.29%
- +1.86%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 3
- 6
- Recent ratings
- 25
- 13
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation
- Boston Scientific downgraded by Raymond James with a new price target
- Boston Scientific announces conference call discussing first quarter 2026 results
- Amendment: SEC Form S-4/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Latest CVRX
- CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
- CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
- SEC Form DEFA14A filed by CVRx Inc.
- SEC Form DEF 14A filed by CVRx Inc.
- CVRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- CVRx Reports Preliminary First Quarter 2026 Financial Results
- Chief Medical Officer Adamson Philip B. was granted 41,000 shares and sold $9,973 worth of shares (1,262 units at $7.90), increasing direct ownership by 182% to 61,578 units (SEC Form 4)
- CHIEF HUMAN RESOURCES OFFICER Morrison Gregory was granted 34,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Morrison Gregory
- PRES & CEO Hykes Kevin sold $61,349 worth of shares (7,763 units at $7.90) and was granted 159,000 shares, increasing direct ownership by 114% to 284,237 units (SEC Form 4)